<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27696">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746159</url>
  </required_header>
  <id_info>
    <org_study_id>CL0026-01</org_study_id>
    <nct_id>NCT02746159</nct_id>
  </id_info>
  <brief_title>Lutonix® Global AV Registry</brief_title>
  <acronym>AVR</acronym>
  <official_title>A Prospective, Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon PTA Catheter for Treatment of Dysfunctional Native and Synthetic AV Fistulae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Registry is to enroll patients presenting with clinical and hemodynamic
      abnormalities in native or synthetic (grafts) arteriovenous (AV) fistulae located in the
      arm. Subjects will be treated with the Lutonix DCB carrying the CE Mark per current IFU and
      followed clinically for a minimum of 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Proportion of subjects with freedom from any serious adverse event(s) involving the AV access circuit</measure>
    <time_frame>30 days.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with target lesion primary patency</measure>
    <time_frame>6 Months</time_frame>
    <description>Defined as the interval following index procedure until clinically-driven reintervention of the target lesion or access thrombosis, through 6 months.
Clinically-driven reintervention is defined as a lesion that has ≥50% stenosis and at least one clinical, physiological or hemodynamic abnormality attributable to the stenosis defined in the K/DOQI guidelines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with access circuit primary patency at 3, 6, and 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Interval following intervention until the next access circuit thrombosis or repeated intervention. Ends with treatment of a lesion anywhere within the access circuit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects withTarget Lesion Primary Patency (TLPP)</measure>
    <time_frame>12 months</time_frame>
    <description>Target Lesion Primary Patency (TLPP) is defined as the interval following index procedure intervention until clinically driven reintervention of the target lesion or access thrombosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects with Abandonment of permanent access in the index extremity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects with Device Success</measure>
    <time_frame>12 Months</time_frame>
    <description>Successful delivery to the target lesion, deployment, and retrieval at index procedure. If a device is inserted into the subject but not used due to user error (e.g. inappropriate balloon length or transit time too long), this device will not be included in the device success assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects with Procedural Success</measure>
    <time_frame>12 Months</time_frame>
    <description>At least one indicator of hemodynamic success (e.g., physical examination with restoration of a thrill, direct measurement of flow) in the absence of peri-procedural (index procedure and through hospital stay) Serious Adverse Device Effects (SADEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects with Clinical Success</measure>
    <time_frame>12 Months</time_frame>
    <description>The resumption of dialysis for at least one session after the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of device and procedure related adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Arteriovenous Fistula</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lutonix 035 Drug Coated Balloon PTA Catheter, Model 9004</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enroll patients presenting with clinical and hemodynamic abnormalities in
        native or synthetic (grafts) arteriovenous (AV) fistulae located in the arm.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant, non-breastfeeding female ≥18 years of age;

          2. Patient is willing to provide informed consent, and is willing to comply with the
             protocol-required follow up visits;

          3. Native or synthetic (grafts) arteriovenous fistula located in the arm, including
             central veins, presenting with any clinical, physiological or hemodynamic
             abnormalities warranting angiographic imaging as defined in the K/DOQI guidelines;
             and

          4. Lesion(s) can be treated with available Lutonix DCB device size matrix per current
             IFU.

        Exclusion Criteria:

        Patients will be excluded if ANY of the following conditions apply:

          1. Patient is currently participating in an investigational drug or device study which
             has not yet reached its primary endpoint or was previously enrolled into this
             registry (i.e. Lutonix Global AV registry).

          2. Patient has a non-controllable allergy to contrast; or

          3. Patient has another medical condition that, which in the opinion of the Investigator,
             may confound the data interpretation of is associated with a life expectancy
             insufficient to allow for completion of patient registry procedure and follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitrios Karnabatidis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Patras, Radiology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Proebe</last_name>
    <phone>+49-4441-937-9897</phone>
    <email>Ruth.Proebe@crbard.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Les Fontaines</name>
      <address>
        <city>Melun</city>
        <zip>77000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Ferrario, Dr.</last_name>
      <phone>+33 1 60 56 61 70</phone>
      <email>angel.ferrario@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik Giessen und Marburg</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrique Alejandre-Lafont, Dr.</last_name>
      <phone>+49 641 985 41 818</phone>
      <email>Enrique.Alejandre-Lafont@radiol.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf Teichgraeber, Dr.</last_name>
      <phone>+49 3641 9-324831</phone>
      <email>Ulf.teichgraeber@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitrios Karnabatidis, Ass. Prof.</last_name>
      <phone>30 2610 999 219</phone>
      <email>karnaby@upatras.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Casa Di Cura Maria Rosaria</name>
      <address>
        <city>Pompei</city>
        <zip>80045</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Saracino</last_name>
      <phone>+ 39 (0)81.5359111</phone>
      <email>guidosaracino@virgilio.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Insubria</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Tozzi, Dr.</last_name>
      <phone>+39-0332-393259</phone>
      <email>matteo.tozzi@uninsubria.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Chirurgii Naczyniowej University Hospital nr 1</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radoslaw Pietura, M.D, Ph.D</last_name>
      <phone>+48 81 538 51 13</phone>
      <email>radoslawpietura@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore City</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jackie Ho Pei</last_name>
      <phone>0065 97223182</phone>
      <email>pei_ho@nuhs.edu.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore City</city>
        <zip>169856</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tze Tec Chong, Dr.</last_name>
      <email>chong.tze.tec@singhealth.com.sg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano</name>
      <address>
        <city>Lugano</city>
        <zip>6903</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josua Van Den Berg, Dr.</last_name>
      <phone>+41 (0)91 811 60 88</phone>
      <email>josua.vandenberg@eoc.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barts and The Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ounali Jaffer</last_name>
      <phone>+4420 346 56314</phone>
      <email>Ounali.Jaffer@bartshealth.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>April 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
